Search results for "Combination"

showing 10 items of 1379 documents

Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society …

2021

International audience; Background and aimsThis European Atherosclerosis Society (EAS) Task Force provides practical guidance for combination therapy for elevated low-density lipoprotein cholesterol (LDL-C) and/or triglycerides (TG) in high-risk and very-high-risk patients.MethodsEvidence-based review.ResultsStatin-ezetimibe combination treatment is the first choice for managing elevated LDL-C and should be given upfront in very-high-risk patients with high LDL-C unlikely to reach goal with a statin, and in primary prevention familial hypercholesterolaemia patients. A proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor may be added if LDL-C levels remain high. In high and very-h…

0301 basic medicinemedicine.medical_specialtyStatinSettore MED/09 - Medicina InternaCombination therapymedicine.drug_classHigh-risk2019 ESC/EAS Dyslipidaemia GuidelineLipid goal030204 cardiovascular system & hematologyTriglyceride03 medical and health sciences0302 clinical medicineCombined treatmentcardiovascular diseaseInternal medicinemedicineHumanstriglycerides2019 ESC/EAS Dyslipidaemia Guidelines; combination treatment; LDL cholesterol; triglycerides; lipid goals; high-risk; cardiovascular diseaselipid goalsbusiness.industryTask forceAnticholesteremic AgentsPCSK9Cholesterol LDL[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismAtherosclerosis2019 ESC/EAS Dyslipidaemia Guidelines3. Good health030104 developmental biologyDiabetes Mellitus Type 2Combination treatmentAtherosclerosiLDL cholesterolEuropean atherosclerosis societyKexinlipids (amino acids peptides and proteins)Proprotein Convertase 9Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessVery high risk
researchProduct

Virotherapy in Germany—Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies

2021

Virotherapy research involves the development, exploration, and application of oncolytic viruses that combine direct killing of cancer cells by viral infection, replication, and spread (oncolysis) with indirect killing by induction of anti-tumor immune responses. Oncolytic viruses can also be engineered to genetically deliver therapeutic proteins for direct or indirect cancer cell killing. In this review—as part of the special edition on “State-of-the-Art Viral Vector Gene Therapy in Germany”—the German community of virotherapists provides an overview of their recent research activities that cover endeavors from screening and engineering viruses as oncolytic cancer therapeutics to their cli…

0301 basic medicinemedicine.medical_treatmentGenetic enhancementvirus targetingMedizinReviewcombination therapychemistry.chemical_compoundDDC 570 / Life sciencesClinical trials0302 clinical medicineKlinisches ExperimentGermanyNeoplasmsMedicineimmunotherapy ; therapeutic transgene ; combination therapy ; Virustherapie ; clinical trials ; virus engineering ; oncolytic virus ; research in Germany ; virus targeting ; virotherapyOncolytic VirotherapyClinical Trials as Topicvirus engineeringKombinationstherapieQR1-5023. Good healthOncolytic VirusesInfectious Diseases030220 oncology & carcinogenesisImmunotherapyvirotherapyGenetic Engineeringresearch in GermanyMicrobiologyVirusViral vector03 medical and health sciencesImmune systemddc:570VirologyAnimalsHumanstherapeutic transgeneVirotherapyoncolytic virusbusiness.industryImmunotherapyVirologyOncolytic virusImmuntherapie030104 developmental biologychemistryVacciniabusinessViruses
researchProduct

Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of a…

2017

Lutz E Pillunat,1 Carl Erb,2 Auli Ropo,3 Friedemann Kimmich,4 Norbert Pfeiffer5 1Department of Ophthalmology, University Hospital Carl Gustav Carus, Dresden, 2Augenklinik am Wittenbergplatz, Berlin, Germany; 3Santen Europe, Helsinki, Finland; 4eyecons, Pfinztal, 5Department of Ophthalmology, Mainz University Medical Center, Mainz, Germany Background: Efficacy, tolerability and safety of the novel preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% (Taptiqom®) were investigated in an observational study in Germany.Objective: To assess efficacy, tolerability and safety of the preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% in a real-life setti…

030213 general clinical medicinemedicine.medical_specialtyIntraocular pressureOpen angle glaucomagenetic structuresfixed combinationGlaucomaTimololOcular hypertension03 medical and health sciences0302 clinical medicineOphthalmologymedicineAdverse effectOriginal Researchpreservative-free medicationbusiness.industrytafluprostTafluprostClinical Ophthalmologymedicine.diseasetimololeye diseasesOphthalmologyglaucomaTolerability030221 ophthalmology & optometrysense organspreservativesbusinessmedicine.drugClinical Ophthalmology (Auckland, N.Z.)
researchProduct

Comparison of CRISPR and marker based methods for the engineering of phage T7

2020

With the recent rise in interest in using lytic bacteriophages as therapeutic agents, there is an urgent requirement to understand their fundamental biology to enable the engineering of their genomes. Current methods of phage engineering rely on homologous recombination, followed by a system of selection to identify recombinant phages. For bacteriophage T7, the host genescmkortrxhave been used as a selection mechanism along with both type I and II CRISPR systems to select against wild-type phage and enrich for the desired mutant. Here we systematically compare all three systems; we show that the use of marker-based selection is the most efficient method and we use this to generate multiple …

0303 health sciences030306 microbiologyMutantComputational biologyBiologybiology.organism_classificationGenomeBacteriophage03 medical and health sciencesLytic cycleCRISPRHomologous recombinationGeneSelection (genetic algorithm)030304 developmental biology
researchProduct

2020

Telomeres have the ability to adopt a lariat conformation and hence, engage in long and short distance intra-chromosome interactions. Budding yeast telomeres were proposed to fold back into subtelomeric regions, but a robust assay to quantitatively characterize this structure has been lacking. Therefore, it is not well understood how the interactions between telomeres and non-telomeric regions are established and regulated. We employ a telomere chromosome conformation capture (Telo-3C) approach to directly analyze telomere folding and its maintenance inS.cerevisiae. We identify the histone modifiers Sir2, Sin3 and Set2 as critical regulators for telomere folding, which suggests that a disti…

0303 health sciencesCancer ResearchSaccharomyces cerevisiaeRAD51Biologybiology.organism_classificationSubtelomereCell biologyTelomereChromatinChromosome conformation capture03 medical and health sciences0302 clinical medicineTelomere HomeostasisGeneticsHomologous recombinationMolecular Biology030217 neurology & neurosurgeryGenetics (clinical)Ecology Evolution Behavior and Systematics030304 developmental biologyPLOS Genetics
researchProduct

Betweenness Centrality for Networks with Non-Overlapping Community Structure

2018

Evaluating the centrality of nodes in complex networks is one of the major research topics being explored due to its wide range of applications. Among the various measures that have been developed over the years, Betweenness centrality is one of the most popular. Indeed, it has proved to be efficient in many real-world situations. In this paper, we propose an extension of the Betweenness centrality designed for networks with nonoverlapping community structure. It is a linear combination of the so-called “local” and “global” Betweenness measures. The Local measure takes into account the influence of a node at the community level while the global measure depends only on the interactions betwe…

0303 health sciencesTheoretical computer scienceComputer scienceNode (networking)Community structure[INFO.INFO-CV]Computer Science [cs]/Computer Vision and Pattern Recognition [cs.CV]Scale (descriptive set theory)Complex network01 natural sciencesMeasure (mathematics)010305 fluids & plasmas03 medical and health sciencesBetweenness centrality0103 physical sciencesCentralityLinear combinationComputingMilieux_MISCELLANEOUS030304 developmental biology
researchProduct

Development of polypeptide-based therapeutics for the treatment of castration resistant prostate cancer

2019

El cáncer de próstata (CaP) es el segundo cáncer más frecuente en los hombres. Los estudios han establecido el gen de fusión (T2E) compuesto por TMPRSS2 (serina proteasa dependiente de andrógenos) y ERG (factor de transcripción de la familia ETS) como un biomarcador potencial de CaP. La progresión en el CaP incluye tanto el receptor de andrógenos (AR) como el receptor del factor de crecimiento de insulina 1 (IGF-1R), y el tratamiento con un anticuerpo anti-IGF-1R (AVE1642) ha demostrado un gran potencial en el tratamiento de los pacientes con CaP T2E-positivos. Por ello, el desarrollo de terapias personalizadas basadas en polímeros terapéuticos puede favorecer el tratamiento de CaP para un …

:CIENCIAS DE LA VIDA::Biología humana [UNESCO]castration resistant prostate cancerpolymer antibody conjugatepolymer therapeuticconfocal microscopy:CIENCIAS DE LA VIDA::Biología molecular [UNESCO]combination therapyabirateroneantibodiescell signalingtumor microenvironmentUNESCO::CIENCIAS DE LA VIDA::Biología molecular:CIENCIAS DE LA VIDA::Bioquímica [UNESCO]orthotopic mice modelflow cytometryUNESCO::CIENCIAS DE LA VIDA::BioquímicaUNESCO::CIENCIAS DE LA VIDA::Biología celularprostate cancernanomedicineUNESCO::QUÍMICA::Otras especialidades químicas:CIENCIAS DE LA VIDA::Biología celular [UNESCO]UNESCO::QUÍMICA::BioquímicaUNESCO::CIENCIAS DE LA VIDA::Biología humanacell trafficking:QUÍMICA::Otras especialidades químicas [UNESCO]:QUÍMICA::Bioquímica [UNESCO]
researchProduct

Perspectives for the Treatment of Brucellosis in the 21st Century: The Ioannina Recommendations

2007

Policy Forum. Competing interests: ER has received research grants from Daiichi, Bayer, and Theravance and has served as a consultant to Pfizer, Theravance, Bayer, Wyeth, Rosetta, and BiondVax. Summary Points Brucellosis remains the commonest anthropozoonosis worldwide, and its treatment remains complex, requiring protracted administration of more than one antibiotic. In November 2006, a consensus meeting aimed at reaching a common specialist statement on the treatment of brucellosis was held in Ioannina, Greece under the auspices of the International Society of Chemotherapy and the Institute of Continuing Medical Education of Ioannina. The author panel suggests that the optimal treatment o…

:Diseases::Pathological Conditions Signs and Symptoms::Pathologic Processes::Disease Attributes::Recurrence [Medical Subject Headings]Veterinary medicine:Chemicals and Drugs::Carbohydrates::Glycosides::Aminoglycosides::Streptomycin [Medical Subject Headings]:Phenomena and Processes::Microbiological Phenomena::Drug Resistance Microbial [Medical Subject Headings]DiseaseGlobal Health:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]:Health Care::Population Characteristics::Health::World Health [Medical Subject Headings]Terminología como AsuntoBrucellosi:Organisms::Eukaryota::Animals [Medical Subject Headings]:Health Care::Health Care Economics and Organizations::Organizations::International Agencies::United Nations::World Health Organization [Medical Subject Headings]Policy ForumMedicine in Developing CountriesGentamicinasDrug Resistance MicrobialBrucelosisAdhesión a DirectrizGeneral MedicineHumanosDrug CombinationsAntibacterianosDoxycyclineStreptomycinEstreptomicinaMedicine:Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds with 4 or More Rings::Rifamycins::Rifampin [Medical Subject Headings]Drug Therapy CombinationGuideline AdherenceRifampinFluoroquinolonesSalud Mundialmedicine.medical_specialtyEfficacyResultado del TratamientoInvestigación BiomédicaRecurrenciaTherapeuticsWorld Health OrganizationMicrobiologyAntibiotic resistanceTerminology as Topic:Disciplines and Occupations::Social Sciences::Internationality::International Cooperation::Developing Countries [Medical Subject Headings]HumansMedical journalIntensive care medicineDeveloping Countries:Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds 1-Ring::Pyrimidines::Trimethoprim::Trimethoprim-Sulfamethoxazole Combination [Medical Subject Headings]medicine.diseaseCotrimoxazoleAnimalesQuimioterapia:Humanities::Humanities::History::History Modern 1601-::History 21st Century [Medical Subject Headings]GentamicinsBrucel·losiBiomedical ResearchCommunicable diseases:Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds 2-Ring::Quinolines::Quinolones::Fluoroquinolones [Medical Subject Headings]Human diseaseRecurrence:Chemicals and Drugs::Pharmaceutical Preparations::Drug Combinations [Medical Subject Headings]:Information Science::Information Science::Communication::Language::Linguistics::Terminology as Topic [Medical Subject Headings]biologyIraqi patientsRMetaanalysis:Diseases::Bacterial Infections and Mycoses::Bacterial Infections::Gram-Negative Bacterial Infections::Brucellosis [Medical Subject Headings]Historia del Siglo XXIAnti-Bacterial AgentsCombinación Trimetoprim-SulfametoxazolTreatment OutcomeInfectious Diseases:Disciplines and Occupations::Natural Science Disciplines::Science::Research::Biomedical Research [Medical Subject Headings]:Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons Cyclic::Hydrocarbons Aromatic::Polycyclic Hydrocarbons Aromatic::Naphthacenes::Tetracyclines::Doxycycline [Medical Subject Headings]Fluoroquinolonas:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Anti-Bacterial Agents [Medical Subject Headings]:Chemicals and Drugs::Carbohydrates::Glycosides::Aminoglycosides::Gentamicins [Medical Subject Headings]Países en Desarrollo:Analytical Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Therapy Combination [Medical Subject Headings]BrucellaHistory 21st CenturyBrucellosisWorld healthTrimethoprim Sulfamethoxazole Drug CombinationmedicineAnimals:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Treatment Outcome [Medical Subject Headings]Resistencia a Medicamentosbusiness.industryOrganización Mundial de la SaludBrucellosisMalalties infecciosesTerapèuticabiology.organism_classificationCombinación de MedicamentosDoxiciclinaTherapybusinessBrucella melitensisPLoS Medicine
researchProduct

Measurement of spin-orbital angular momentum interactions in relativistic heavy-ion collisions

2020

The first evidence of spin alignment of vector mesons ($K^{*0}$ and $\phi$) in heavy-ion collisions at the Large Hadron Collider (LHC) is reported. The spin density matrix element $\rho_{00}$ is measured at midrapidity ($|y| <$ 0.5) in Pb-Pb collisions at a center-of-mass energy ($\sqrt{s_{\rm NN}}$) of 2.76 TeV with the ALICE detector. $\rho_{00}$ values are found to be less than 1/3 (1/3 implies no spin alignment) at low transverse momentum ($p_{\rm T} <$ 2 GeV/$c$) for $K^{*0}$ and $\phi$ at a level of 3$\sigma$ and 2$\sigma$, respectively. No significant spin alignment is observed for the $K^0_S$ meson (spin = 0) in Pb-Pb collisions and for the vector mesons in $pp$ collisions. The meas…

:Kjerne- og elementærpartikkelfysikk: 431 [VDP]heavy ion: scatteringPhysics::Instrumentation and Detectorsheavy ion collisionsNuclear TheoryHadronGeneral Physics and AstronomyhiukkasfysiikkaGLOBAL POLARIZATION; ALIGNMENT; MESONS; LAMBDA; QCDhyperonnucl-ex01 natural sciences2760 GeV-cms/nucleonRelativistic heavy ionspin-orbitalHeavy ion experimentsHigh Energy Physics - ExperimentHigh Energy Physics - Experiment (hep-ex)ALICE[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Nuclear Experiment (nucl-ex)spin: density matrixNuclear ExperimentNuclear ExperimentPhysicsPhysicselliptic flowElliptic flowVDP::Kjerne- og elementærpartikkelfysikk: 431spin: alignmentMESONSvector mesonHadronizationLAMBDAddc:PRIRODNE ZNANOSTI. Fizika.ALIGNMENT:Nuclear and elementary particle physics: 431 [VDP]CERN LHC CollVDP::Nuclear and elementary particle physics: 431Spin-orbit angular momentumParticle Physics - ExperimentQuarkAngular momentumMesonFOS: Physical sciencestransverse momentum[PHYS.NEXP]Physics [physics]/Nuclear Experiment [nucl-ex]Physics and Astronomy(all)Relativistic heavy ionsangular momentum114 Physical sciences530Nuclear physicspolarization: measuredSpin-orbit angular momentum heavy ion collisions0103 physical sciencesddc:530decay: angular distributionNuclear Physics - ExperimentVector mesonGLOBAL POLARIZATION010306 general physicsNuclear Physicshep-exHigh Energy Physics::PhenomenologyHyperonQCDNATURAL SCIENCES. Physics.recombinationRelativistic heavy ions; spin-orbitalspin (kvanttimekaniikka)correlationHigh Energy Physics::Experimentquark: polarizationspin-orbital angular momentum interactions ; heavy-ion collisionshadronizationexperimental results
researchProduct

Chemical Compositions and Antioxidant Activities of Essential Oils, and Their Combinations, Obtained from Flavedo By-Product of Seven Cultivars of Si…

2022

In this work, seven Citrus aurantium essential oils (EOs) derived from flavedo of cultivars &lsquo;Canaliculata&rsquo;, &lsquo;Consolei&rsquo;, &lsquo;Crispifolia&rsquo;, &lsquo;Fasciata&rsquo;, &lsquo;Foetifera&rsquo;, &lsquo;Listata&rsquo;, and &lsquo;Bizzaria&rsquo; were investigated. EOs were also combined in 1:1 (v/v) ratio to identify possible synergism or antagonism of actions. GC-MS analysis was done to investigate Eos&rsquo; phytochemical profiles. The antioxidant activity was studied by using a multi-target approach based on FRAP, DPPH, ABTS, and &beta;-carotene bleaching tests. A great difference was observed in EOs&rsquo; phytochemical profiles. d-limonene (33.35&ndash;89.17%) w…

<i>Citrus aurantium</i>; GC-MS analysis; essential oil combinations; <span style="font-variant: small-caps">d</span>-limonene; PCA analysis; global antioxidant scoreOrganic ChemistryPharmaceutical ScienceGC-MS analysid-limoneneAnalytical Chemistryglobal antioxidant scoreChemistry (miscellaneous)Drug Discoveryessential oil combinationMolecular MedicinePCA analysiPhysical and Theoretical ChemistryCitrus aurantiumMolecules
researchProduct